Purpose: The vascular disrupting agent ombrabulin rapidly reduces tumor blood flow and causes necrosis in vivo. A phase I dose-escalation study was designed to determine the recommended phase II dose (RP2D) of single-agent ombrabulin administered once every three weeks in patients with advanced solid malignancies.
Introduction
Vascular disrupting agents (VDA) show varying degrees of success in the clinical setting. Ombrabulin (AVE8062, AC-7700) is an analog of the water-soluble VDA combretastatin A4 phosphate (CA4P). These drugs act by disrupting the architecture of established tumor blood vessels following binding to the colchicine site of tubulin, inhibiting polymerization, and resulting in reorganization of the cytoskeleton and changes in cell shape (1, 2) . Ombrabulin shows cytotoxic activity by blocking cell proliferation, induces endothelial cell detachment, and causes constriction of the arteriolar system. The resulting reduction in tumor blood flow leads to tumor necrosis and suppression of tumor growth in a variety of different cancers in vivo (3, 4) . Restriction of tumor blood perfusion and decreased interstitial fluid pressure occur rapidly; in mice this has been reported as early as 15 minutes after ombrabulin infusion, peaking after 6 hours with permanent widespread tumor necrosis after 24 hours (5) . As with other VDAs, perfusion changes seen in normal tissues were largely reversible (6) , indicating that tumor tissue is more susceptible to ombrabulin-induced blood volume reduction (7) .
In animal toxicology studies, ombrabulin mainly affected rapidly proliferating cells, notably circulating blood cells, bone marrow, and the intestinal tract (8) . Neurotoxicity was also reported. Cardiovascular toxicity, characteristic of VDAs (9) , was seen with high-dose ombrabulin in different species, notably degeneration and necrosis of heart tissue and subsequent mineralization and fibrosis (8) . Increases in the cardiac markers creatine kinase MB (CK-MB) and troponin I occurred, along with changes in arterial blood pressure, heart rate, and electrocardiograms (ECG). In mice, myocardial necrosis was absent at 30, <45, and 30 mg/m 2 ombrabulin with single, weekly, and daily for 5-day dosing, and ECG changes were absent at 10, 5, and 10 mg/m 2 , respectively, in dogs.
Three first-in-man phase I dose-escalation clinical studies were initiated in parallel to establish the optimal administration schedule of single-agent ombrabulin. All were designed to evaluate dose-limiting toxicity (DLT) and define the safety profile to establish the recommended phase II dose (RP2D). For all three schedules, ombrabulin was administered as a 30-minute intravenous infusion. Two schedules (daily for 5 consecutive days every 3 weeks and weekly for 3 consecutive weeks every 4 weeks) were abandoned prematurely in light of cardiovascular DLTs (10) . The safety and efficacy results of the third schedule, a once every 3 weeks administration, are presented here, including extensive cardiovascular monitoring and QT analysis. A pharmacokinetic analysis was conducted including evaluation of the potential inhibitory effect of ombrabulin on cytochrome activity. Circulating endothelial cells (CEC), circulating endothelial progenitor cells (CEP), and CEP-mobilizing plasma factors were assessed as potential biomarkers of ombrabulin activity.
Patients and Methods

Patient selection
Adult patients with advanced histologically or cytologically proven solid malignant tumors refractory to conventional treatment or without standard therapeutic options were eligible. Patients had to have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less, adequate hematologic, renal, and hepatic function, adequate washout since prior therapy, and recovery from toxicity. Patients with grade 2 or higher peripheral neuropathy or ototoxicity according to the National Cancer Institute Common Terminology Criteria (NCI-CTC) were excluded, as were those having prior intensive chemotherapy with autologous stem cell rescue, chest irradiation, or a high cumulative anthracycline dose, a history of cardiac conditions, left ventricular ejection fraction (LVEF) <50%, hypertension (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg), antihypertensive treatment, Q-wave infarction or ST segment changes >1 mm (12-lead ECG), or ventricular tachycardia (Holter ECG). Additional exclusion criteria for an ancillary cardiovascular QT study initiated in March 2008 were, NCI-CTC v. 3.0 grade 2 or higher Fridericia-corrected QT interval (QTcF) prolongation, a history of high degree AV block, a pacemaker, atrial fibrillation or flutter, torsade de pointes, congenital long QT syndrome, a family history of long QT syndrome, or sudden death.
The study was approved by the local and national ethics committees and was conducted in accordance with the Declaration of Helsinki. All patients gave written informed consent before enrollment.
Study design
This international phase I dose-escalation study was conducted in 4 centers between June 2002 and October 2009. The extended study period was due to early cardiovascular safety concerns in the parallel phase I studies resulting in a hold on all studies and a subsequent QTc analysis in an expanded cohort at the RP2D. In the first step, ombrabulin doses were escalated to determine the RP2D, and in a second step, additional patients were recruited at this dose for the ancillary QT study. Ombrabulin (Sanofi) was administered as a 30-minute intravenous infusion every 3 weeks using a starting dose of 6 mg/m 2 up to a planned maximum of 72 mg/m 2 . The starting dose was based on animal data, and a conservative dose-escalation approach was initiated with 1 patient per dose level and an additional 2 patients if DLT occurred during the first cycle. Escalation was based on safety (with a cardiac focus) and pharmacokinetic data. Following safety concerns in the two parallel phase I trials, the escalation design was modified and 8 patients were included at each dose level from 8 to 25 mg/m 2 , then 6 patients per dose level from 30 mg/m 2 . The maximum-tolerated dose (MTD) was the dose at which 2 or more patients had DLT during the first cycle. The RP2D was the highest dose at which not more than 1 of at least 6 patients had DLT during the first cycle taking into account the overall safety profile. Antihypertensive agents could
Translational Relevance
Ombrabulin, a vascular disrupting agent, has shown promising preclinical activity. The current study describes the first clinical evaluation of this combretastatin analog when administered as monotherapy in patients with advanced solid tumors. The recommended single-agent dose was established and the toxicity profile was consistent with that of combretastatin. Evidence of antitumor activity with ombrabulin monotherapy was reported. Preliminary results show increases in circulating endothelial cells (CEC), matrix metalloproteinase (MMP)-9, and VEGF following ombrabulin administration. Further studies are merited to determine the role of these pharmacodynamic parameters as potential biomarkers of ombrabulin activity. Optimal use of ombrabulin is expected when combined with other agents and evaluation of ombrabulin activity in combination with other anticancer agents is now underway.
be given if chronic use was required or in the event of isolated blood pressure increase, but were not given as prophylaxis. Treatment of tumor pain was administered as appropriate.
Patients receiving at least one ombrabulin administration with clinical and laboratory examinations during the first cycle were evaluable for DLT, which was defined as any one of: grade 4 thrombocytopenia, grade 4 neutropenia lasting more than 5 days, grade 4 febrile neutropenia, any grade 3-4 nonhematologic toxicity (other than nausea, vomiting, and hypersensitivity), or any of the following cardiovascular events: documented angina pectoris, systolic blood pressure !180 mmHg and/or diastolic blood pressure !110 mmHg, blood pressure variations (systolic, !40 mmHg; diastolic, !30 mmHg), grade !2 hypotension and/or systolic blood pressure <90 mmHg (blood pressure changes had to be shown in at least two successive measurements made at 30-minute intervals), troponin I or CK-MB increase above myocardial necrosis limits, ST segment elevation or depression !1 mm in at least two contiguous leads or Q-wave infarction on a 12-lead ECG, severe ventricular arrhythmia or ST segment elevation/depression !2 mm lasting !1 minute on a Holter ECG, grade 2 or higher LVEF, or cerebral edema consistent with acute ischemia. A 1-week treatment delay was permitted for related toxicity and a 3-week delay for nonrelated toxicity. Dose reduction could be implemented following DLT, grade 2 peripheral neuropathy, or repeated delay with resolved toxicity. Treatment was stopped if a cardiovascular DLT occurred.
Safety and tumor evaluations
Patients were evaluated for adverse events (including cycle 1 DLT and laboratory changes) from weekly physical and neurologic examinations, which were graded according to the NCI-CTC version applicable at the time of the event. Hematology was evaluated twice weekly and biochemistry weekly. A kidney Doppler ultrasound was conducted after the first two infusions and every two cycles thereafter to evaluate long-term renal toxicity. The following cardiovascular evaluations were made before each infusion and then as follows: a clinical examination (twice on the day of infusion), a 12-lead ECG, ambulatory blood pressure monitoring (every 15 minutes for 4 hours, then every 30 minutes for 20 hours), a 24-hour Holter ECG, CK-MB, and troponin I evaluation (10 hours, 1 and 7 days postinfusion). An echocardiography, radionuclide ventriculography and a brain MRI were conducted every other cycle from the second cycle. In the subsequent ancillary QT study, evaluation of ombrabulin for QTcF (which is considered the most appropriate choice in cases of faster heart rate) and other cardiovascular parameters was conducted in patients treated at the RP2D. A linear mixed model was used to evaluate postinfusion changes in QTcF in cycle 1 from a 24-hour Holter ECG (15 and 30 minutes postinfusion start, 10, 25, 45 minutes, 1, 2, 4, 6, 8, and 10 hours postinfusion end, in triplicate). Holter recordings were read centrally and all clinical cardiovascular data were reviewed by an independent cardiology expert. Clinical tumor evaluations were conducted every cycle and radiographic evaluations every other cycle. Tumor response was determined according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0 (11) in patients with at least one postbaseline evaluation.
Pharmacokinetics
The pharmacokinetics of ombrabulin and its metabolite RPR258063 were assessed using 2-mL blood samples collected in heparinized tubes preinfusion, immediately before the end of the 30-minute infusion, and at 5, 10, 20, 30, 45, and 60 minutes, 2, 4, 6, 12, and 24 hours postinfusion in cycle 1. Samples at 25 minutes (replacing 20 and 30 minutes), 48 hours, immediately before infusion-end at cycle 2, and 10 minutes postinfusion were added subsequently. Samples were assayed with a validated liquid chromatography/tandem mass spectrometry (LC/MS-MS) method using a 2.0 ng/mL limit of quantification (LOQ) for both analytes. Noncompartmental analyses were performed including C max (maximum plasma concentration), AUC (0-t) (area under the plasma concentration-time curve from 0 to the last measurable concentration at time t), t 1/2Z (terminal half-life), AUC (area under the plasma concentration-time curve from 0 to infinity on Day 1), CL (total body clearance of drug from the plasma), V ss (apparent volume of distribution at steady-state) (WinNonlin, version 3.3, Scientific Consulting Inc.).
The effect of ombrabulin on CYP1A2 and CYP2C19 activity was evaluated in a subset of patients using caffeine and omeprazole tests, respectively. If the median CYP1A2 phenotype index at the previous ombrabulin dose level changed by 50% or more, the effect on CYP3A4 activity was evaluated using the midazolam test. Following an 8-hour fast, 100 mg caffeine or 30 mg omeprazole was administered with 240 mL noncarbonated water during screening, then 15 minutes after the end of the ombrabulin infusion on day 1 of cycle 1. Midazolam 0.025 mg/kg was administered intravenously between 7 and 4 days before the ombrabulin infusion and 30 minutes after, on day 1 of cycle 1 or 2. Blood samples (4 mL) were collected immediately before and then 2 (omeprazole) or 5 hours (caffeine) after the end of the administration and at 15 and 30 minutes, 1.0, 1.5, 2.0, 3.5, and 5.5 hours after midazolam administration. Plasma concentrations of caffeine and 1,7-dimethylxanthine were analyzed by validated high-performance liquid chromatography (HPLC) with UV absorbance detection with an LOQ of 25 ng/mL. Plasma concentrations of omeprazole, 5-hydroxy-omeprazole (LOQ of 1 ng/mL for both compounds), and midazolam (LOQ of 0.1 ng/mL) were analyzed by a validated HPLC assay with tandem mass spectrometry (MS-MS) detection. Phenotypic indices for CYP1A2 (dimethylxanthine/caffeine ratio) and CYP2C19 (omeprazole/5-hydroxy-omeprazole), C max , AUC, AUC (0-t) , and t 1/2z of midazolam were calculated (WinNonlin, version 3.3; Scientific Consulting Inc.). Parameters were analyzed using a linear mixed effects model (fixed term for treatment and an unstructured R-variance-covariance matrix for subject blocks). Estimates and 90% confidence intervals (CI) for the ratios were computed.
Quantification of CECs, CEPs, and plasma factors
Patients receiving 50 mg/m 2 ombrabulin were evaluated (Institut Gustave Roussy, Villejuif, France). Blood samples were collected before infusion for all analyses, then at 6, 10, and 24 hours and 6 or 7 days postinfusion for CECs, on days 3 and 7 for CEPs, and at 6 hours, 1, 2, and 6 or 7 days postinfusion for plasma factors. CECs, identified as CD31 þ CD146 þ CD45 À 7-amino-actinomycin D (7-AAD) À viable cells, were measured by four-color flow cytometry (12) . For CEP analysis, bone marrowderived VEGFR2 þ progenitor cells, identified as CD45
, were measured after Ficoll gradient enrichment by flow cytometry (13) . CEC and CEPs were acquired on a FACSCalibur (BD Biosciences) and analyzed using CELLQuest 3.2 software. CEPs were expressed as the percentage of VEGFR2 þ cells among circulating
[VEGF, matrix metalloproteinase (MMP)-9, granulocyte colony-stimulating factor (G-CSF), and SDF-1 (stromal cell-derived factor)] were assessed in duplicate using commercial ELISA kits (R&D System). Optical density was plotted against a standard curve and values at least twice background noise were considered relevant. Data were analyzed using SPSS software (version 15.0) and evaluated with nonparametric two-sided Mann-Whitney tests. P 0.05 were considered significant.
Results
Patient characteristics and treatment
Patient characteristics of the 105 patients treated are summarized in Table 1 . The most common tumors were colorectal (30%) and ovarian (27%). Seventy-three patients were treated at 11 dose levels from 6 to 60 mg/m 2 ombrabulin during the dose-escalation step. Once the RP2D was established (50 mg/m 2 ), this dose level was expanded to a total of 39 patients, with a median of two cycles (range, 1-8) administered at this dose level ( Table 2) .
Dose-limiting toxicity
Of the 73 patients treated during the dose escalation part of the study, 1 was incompletely evaluated for safety in the first cycle and was not evaluable for DLT. No DLT was reported during dose escalation up to and including 42 mg/ m 2 (dose level 9). Of the 7 patients initially treated at 50 mg/m 2 , 1 had a DLT of grade 3 abdominal pain on the day of the ombrabulin infusion. The dose was escalated to 60 mg/m 2 and the first patient treated had two DLTs: grade 3 tumor pain (lasting less than 24 hours) and grade 3 hypertension. Although the MTD was not reached, these toxicities were considered clinically relevant and 50 mg/m 2 was selected as the RP2D. Of the 32 additional patients treated in the RP2D expansion cohort, 4 had events corresponding to the DLT definition during cycle 1: grade 3 sciatica/grade 3 hypertension, grade 4 acute myocardial infarction, grade 2 angina pectoris/grade 3 presyncope/grade 3 somnolence (all on the day of infusion, resolving within 2 days), and grade 3 melena (19 days postinfusion, resolving 3 days later).
Overall safety
At the RP2D, the most common drug-related adverse events were headache (31% of patients), asthenia (28%), abdominal pain (26%), nausea (26%), diarrhea (23%), and hypertension (23%; Table 2), and were mainly mild to moderate. Nausea and vomiting were reported at a wide range of dose levels, whereas headache, asthenia, abdominal pain, diarrhea, hypertension, and chest pain were more common at higher dose levels. Tumor pain was reported in 7 patients and paresthesia in 6, mainly at higher doses.
With the exception of laboratory abnormalities, grade 3-4 related toxicity was only reported at the three highest dose levels evaluated, were almost all grade 3, and rarely occurred in more than 1 patient (Table 3) . Grade 3 events included tumor pain, abdominal pain, melena, presyncope, sciatica, somnolence, hyperkalemia, and cardiovascular events of hypertension, increased brain natriuretic peptide (BNP), troponin I, and thrombosis. One patient (50 mg/m 2 ) who was receiving antihypertensive medication had grade 4 acute myocardial infarction associated with increased troponin levels (0.66 ng/mL) and ST segment depression. Treatment was discontinued as a result of toxicity for this A retrospective cardiologic evaluation confirmed on-site findings. Grade 1/2 hypertension, which was not reported from bedside monitoring, was identified from 24-hour blood pressure monitoring in 2 additional patients (8 and 50 mg/m 2 ), both of which matched the DLT definition. Most blood pressure increases corresponded to grade 1/2 hypertension, were transient (<5 hours), dose-dependent, asymptomatic, and did not require corrective treatment. Cardiac marker elevations were rare and no dose-dependent trends were reported. All LVEF decreases were less than 10% below normal ranges and were not dose-dependent.
ECG analysis was conducted in 38 patients treated at 50 mg/m 2 with available evaluable Holter recordings. An initial decrease in heart rate was seen over the 2 hours after the end of the infusion (maximal mean decrease of 12.2 bpm after 10 minutes), followed by an increase reaching a maximum after 4 hours (mean increase of 15.6 bpm), after which it gradually decreased, with a mean elevation of 6.1 bpm reported 10 hours postinfusion (Supplementary Fig.  S1A ). None of the 37 patients who could be evaluated for QTcF had clinically significant QTcF prolongations and the maximal estimated mean change from baseline was a 4.1 milliseconds increase (90% CI, 0.94-7.3) at 4 hours postinfusion ( Supplementary Fig. S1B ). Four of 37 patients with normal baseline QTcF values had an increase of more than 450 milliseconds and/or a relative increase of 30 to 60 milliseconds. A linear mixed effects model of QT interval versus drug exposure gave an estimated slope of À0.001 ms/ng/mL for ombrabulin and 0.003 ms/ng/mL for RPR258063, suggesting that QTcF is generally stable with increasing concentrations of ombrabulin or RPR25806 (Supplementary Fig. S2 ).
Laboratory abnormalities, although common, were mainly mild to moderate, and were present at similar frequencies at most dose levels (Tables 2 and 3 ). Anemia was observed in 75% of patients on study (including grade 3 in 6 patients and grade 4 in 1 patient), but was present in 46% of patients at baseline. Lymphopenia was observed in 40% of patients on study and leucopenia in 20%. No grade 3-4 neutropenia or thrombocytopenia occurred. Elevations in liver function enzymes (alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase) were reported in 42% to 49% of patients and hyperbilirubinemia in 24%. Grade 3 enzyme elevations occurred in 7 patients with liver metastases, 4 of whom had disease progression. One patient had grade 4 creatinemia. Antitumor activity A total of 102 patients were evaluable for tumor response according to RECIST (3 patients at 50 mg/m 2 did not have postbaseline evaluations due to early withdrawal; Supplementary Table S1 ). One patient with rectal cancer treated at 50 mg/m 2 had a confirmed partial response lasting 3 months. Stable disease was reported in 27 patients (26%) at all dose levels from 11.5 to 50 mg/m 2 in a range of tumor types including ovarian, colorectal, uterine, and renal cancers. Median duration of stable disease was 2.9 months (range, 1.2-6.0), including 8 patients with stable disease lasting more than 4 months (6 ovarian, 1 adrenal, and 1 retroperitoneum).
Pharmacokinetics
The pharmacokinetics of ombrabulin and its active metabolite RPR258063 was evaluated in 104 patients with available samples (Table 4) . For ombrabulin, exposure increased proportionally over the dose range tested and was slightly less than proportional for RPR258063 (Fig. 1A-D) . Elimination was biphasic with ombrabulin rapidly converted to RPR258063 (mean half-life 17.4 minutes for first dose) and high clearance (mean, 53.3 L/h/m 2 for the first dose), whereas the steady state volume of distribution was low (15.9 L/m 2 ). For RPR258063, a biphasic or triphasic elimination profile was observed with a terminal half-life of 8.7 hours. A representative plasma concentration-time profile in a patient treated at the RP2D is shown in Fig. 1E . The overall metabolic ratio (AUC RPR258063/AUC ombrabulin) was 2.3. Interindividual variability was high for C max and AUC for both ombrabulin and RPR258063. No trend was observed between ombrabulin C max at cycle 1 and 2.
The effect of ombrabulin on CYP1A2 and CYP2C19 activity was evaluated in 23 patients (treated at 8-25 mg/m 2 ). No clinically relevant changes in the dimethylxanthine to caffeine ratio were seen when caffeine was coadministered with ombrabulin (1.17; 90% CI, 1.00-1.37; N ¼ 10) indicating that CYP1A2-mediated drug metabolism was not inhibited. Coadministration of omeprazole gave an estimated omeprazole versus 5-hydroxyomeprazole ratio of 1.26 (90% CI, 0.82-1.93; N ¼ 19) indicating weak inhibition of the CYP2C19 isoform pathway. The effect of ombrabulin on CYP3A4 was evaluated in 13 patients treated at 20 to 50 mg/ m 2 . Changes were marginal with coadministration of midazolam (mean ratio of with ombrabulin to without for C max 0.77; 90% CI, 0.40-1.50 and AUC (0-t) 0.83; 90% CI, 0.50-1.38), suggesting no inhibition of the CYP3A4 isoform pathway. Moderate to high inter-and intraindividual variability was reported in midazolam pharmacokinetics.
Plasma biomarkers
CECs, CEPs, VEGF, MMP-9, G-CSF, and SDF-1 were evaluated in 17 patients treated at 50 mg/m 2 . Of the 15 patients who were evaluable for CECs, 11 had an increase of more than 10 cells/mL (considered biologically relevant) for at least one time point postinfusion, at 6 (4 patients), 10 (8 patients), 24 hours (7 patients), and day 6 or 7 (4 patients). Seven patients responded at two or more time points. Peak CEC counts were detected at 10 hours in 5 patients and at 24 hours in 4 patients. CECs were significantly increased at 10 hours (median, 28 cells/mL vs. 11 cells/mL at baseline; P ¼ 0.03; Fig. 2A ) compared with baseline. For CEP evaluations, the range in values was wide at all time points and median levels in evaluable patients at day 2 (1.8%; range, 0%-24.1%; N ¼ 12) and day 6 or 7 (1.8%; range, 0.1%-4.7%; N ¼ 16) were not significantly different from baseline (2.7%; range, 0.3%-32.5%). Evaluation of CEP-mobilizing plasma proteins showed a wide range of interpatient values. Median VEGF and MMP-9 levels at 6 hours postinfusion were significantly higher as compared with baseline (P ¼ 0.03; Fig. 2B and C) . No significant differences were reported at any of the time points with SDF-1, and G-CSF was undetectable in all but 1 patient.
Discussion
In this study, a 30-minute infusion of 50 mg/m 2 ombrabulin was established as the RP2D. Two patients had three DLTs in cycle 1 during dose escalation, specifically grade 3 abdominal pain (50 mg/m 2 ) and grade 3 tumor pain/grade 3 hypertension (60 mg/m 2 ). Cohort expansion at the RP2D allowed a thorough safety evaluation. The single-agent toxicity profile included mild to moderate headache, asthenia, abdominal pain, gastrointestinal toxicities, hypertension, anemia, and lymphopenia. These toxicities correspond to the safety profile of combretastatin (14, 15) , although dose-related tumor pain, a prominent toxicity associated with VDAs (16, 17) , was relatively uncommon (8% of patients vs. 35% with combretastatin; ref. 15 ) with grade 3 in only 2 patients treated at the two highest doses. A small phase I single-agent dose-escalation study following the once every 3 weeks schedule was launched in Japan. The safety profile reflected that of the largely Caucasian population reported here, although toxicities were generally more common; related events at the RP2D included diarrhea (83%), nausea (83%), and hypertension (67%), whereas no severe myelotoxicity or cardiotoxicity was observed (18) .
During the parallel evaluation of the three ombrabulin schedules, four potentially drug-related vascular events (myocardial ischemia, transient asymptomatic hypotension, transient cerebral ischemia, and asymptomatic ventricular tachycardia) were reported in the two other schedules, whereas none had been reported with the once every 3 weeks schedule at that time (dose level 22 mg/m 2 ; ref. 10 ). This prompted a decision to pursue only the current schedule. Given the nature of the reported DLTs, cardiovascular monitoring was intensified with additional evaluations of potential renal vasoconstriction, ventricular function, and continuous Holter tests. Brain MRIs were introduced after the occurrence of transient cerebral ischemia in the weekly Table 4 . Pharmacokinetic parameters following a 30-minute ombrabulin intravenous infusion in cycle 1 (mean
AUC (ngÁhr/mL) 2 ) with rapid recovery in the absence of prophylactic treatment and chest pain (50 mg/m 2 only), and led to treatment discontinuation or dose reduction in 5 patients. Severe cardiotoxicity was infrequent and generally transient with rapid recovery, with only one grade 4 event (myocardial infarction). Given the QTc interval prolongations seen with combretastatin and ASA404 (19, 20) , we analyzed QTcF which is considered more appropriate than the Bazzett's formula in cases of increased heart rate, as is often associated with this class of drugs. However the maximal mean QTcF prolongation at the ombrabulin RP2D (4.1 milliseconds; 90% CI 0.94-7.3) was well below the 20-millisecond threshold recommended for the registration of oncology agents, suggesting its effect on ventricular repolarization in humans is acceptable according to the ICH E14 guideline. Furthermore, LEVF and cardiac marker evaluations did not raise any concerns. Close surveillance of cardiotoxicity, notably for early detection and control of hypertension, along with appropriate patient selection, are essential for successful implementation of VDA therapies (9) . By combining this approach with dose reductions, interruptions, and appropriate curative therapy, effective management of this toxicity is feasible for ombrabulin. Pharmacokinetics confirmed the rapid conversion of ombrabulin to its active metabolite. Ombrabulin and RPR258063 have biphasic and biphasic/triphasic elimination profiles, respectively, with half-lives of 17.4 minutes and 8.7 hours. Exposure increased proportionally with dose for ombrabulin and slightly less than proportionally for RPR258063. At the clinical doses used, ombrabulin showed a trend for weak inhibition of CYP2C19 and no inhibition of the CYP1A2 and CYP3A4 isoforms, suggesting there is no contraindication to ombrabulin use with drugs metabolized via these pathways.
Promising preclinical demonstrations of antitumor activity with ombrabulin have been reported in various murine models in vivo, including ovarian and colon cancers (4, 21) , the most common cancer types in this study. A 28% rate of clinical benefit was seen at the RP2D, including one partial response lasting for 3 months in a patient with rectal cancer and stable disease lasting for more than 4 months in 8 patients, including 6 with ovarian cancer.
A recent study showed that CEPs are key contributors to tumor neoangiogenesis and growth and regulate the angiogenic switch promoting metastatic progression (22) . Experiments in tumor-bearing mice have shown that following VDA treatment, a cascade of biologic events leads to systemic mobilization of CEPs, which are recruited for tumor vascular regeneration, inducing repair (23, 24) . CECs and CEPs have been extensively studied as predictive/prognostic biomarkers for antiangiogenic treatment efficacy including in the context of phase I studies (25, 26) but have also been proposed as quantitative pharmacodynamic biomarkers of VDA bioactivity (24) . In the current study, a significant increase in CECs was reported with a peak, potentially reflecting maximal acute vascular damage, at 10 hours post-ombrabulin infusion. This is in accordance with recent results from an ombrabulin/cisplatin combination phase I study (27) . However, unlike the combination study, there was little evidence in the current study of increased CEP levels. Individual variations in timing of CEP mobilization as well as an effect of cisplatin might explain this difference. It is of note that VEGF and MMP-9 levels, which were significantly increased within 6 hours of ombrabulin administration, are key mediators of CEP mobilization. Furthermore, bone marrow-derived myelomonocytic cells expressing MMP-9 play a critical role in neovascular remodeling (28, 29) . Given the variations in timing of responses, it may be valuable to conduct CEC and CEP measures at multiple time points to determine optimal timing for use of this parameter as a biomarker. The cytokines G-CSF and SDF-1, previously implicated in the acute mobilization of endothelial progenitor cells by VDAs (27, 30) , showed no evidence of being reliable biomarkers of ombrabulin activity. The use of CECs, VEGF, and MMP-9 as biomarkers of ombrabulin activity merits further exploration, as does the use of dynamic contrast-enhanced (DCE) techniques to correlate tumoral vascular changes with antitumor activity (see Supplementary text for a preliminary DCE analysis of this study).
Treatment with VDAs is typically associated with a narrow rim of viable tumor cells surrounding a central necrosis, with endothelial cells promoting proliferation and rapid repopulation of tumors (31) . This biologic phenomenon compromises the efficacy of VDAs as single agents. Optimal use of VDAs will most likely require treatment combination to eradicate the entire tumor (32) . Furthermore, as lower ombrabulin doses are likely to be used in combination therapy, dose-dependent toxicities may well be less frequent.
This study shows that 30-minute infusion of 50 mg/m 2 ombrabulin administered once every 3 weeks as a single agent seems to have manageable side effects. Given that the use of VDAs is likely to be revealed when used in combination with chemotherapy, this schedule is under development in combination with other anticancer agents.
Lower starting doses will be used to curtail possible overlapping toxicities. Promising synergistic activity reported with an ombrabulin/cisplatin combination (33) is currently being assessed in a phase III study in patients with advanced soft tissue sarcoma (NCT00699517). A phase I study of ombrabulin combined with bevacizumab is also underway (34) . 
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